Novo Nordisk is positioned as a durable No. 2 in the obesity drug market, not a loser to Eli Lilly. Click here to read an ...

GLP-1 medications, such as Ozempic, Zepbound and Wegovy, have emerged as a significant advancement in the treatment of various conditions, including Type 2 diabetes, heart ...

Eli Lilly (NYSE:LLY) stock is down 5% in Tuesday afternoon trading, with shares falling to $937 from a prior close of $989.12 ...

For in-store pharmacy chains, the rise of weight-loss drugs represents a business opportunity to reshape shopping habits.

A new analysis from the Center for American Progress examines the Trump administration’s flagship drug pricing portal and finds that TrumpRx, which the president has called “one of the most ...

Premiums have more than doubled for millions of Americans since enhanced Affordable Care Act tax credits expired, and ...

GLP-1 therapy Zepbound has become the biggest weight loss drug since its introduction, outpacing Novo Nordisk’s (NYSE:NVO) ...

With the launch of such a service, questions surrounding what it is exactly and its efficacy in reducing drug prices have been a prominent discussion. Below, we answer some frequently asked questions ...

Kroger said it is now stocking Eli Lilly's injection pen version of the weight-loss drug Zepbound, and will allow self-pay customers to use Lilly's savings card at its retail pharmacies. The ...

Kroger is now offering Zepbound KwikPen, a multidose version of Eli Lilly’s GLP-1 weight loss drug, at participating retail pharmacy locations. The rollout marks the first time self-pay patients may ...

Consumers are paying in cash in a hotly competitive marketplace, creating a rare phenomenon for a relatively new class of prescription drugs: falling prices.